

05 June 2018
EMA/HMPC/444243/2015
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Pelargonium sidoides* DC and/or *Pelargonium reniforme* Curt., radix

Final

The European Medicines Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: A systemic review and meta-analysis. *Phytomedicine* 2008, 15: 378-385

Bachert C, Schapowal A, Funk P, Kieser M. Treatment of acute rhinosinusitis with the preparation from *Pelargonium sidoides* EPs® 7630: a randomized, double-blind, placebo-controlled trial. *Rhinology* 2009, 47: 51-58

Beil W, Kilian P. EPs® 7630, an extract from *Pelargonium sidoides* roots inhibits adherence of *Helicobacter pylori* to gastric epithelial cells. *Phytomedicine* 2007, 14: 5-8

Bereznov VV, Riley DS, Wassmer G, Heger M. Efficacy of extract of *Pelargonium sidoides* in children with acute non-group A beta-haemolytic streptococcus tonsillopharyngitis: a randomized, double-blind, placebo-controlled trial. *Altern Ther Health Med* 2003, 9: 68-78

BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte). Abwehr von Gefahren durch Arzneimittel, Stufe II - Pelargonium-Wurzel-haltige Arzneimittel. 75-3822-V-14588 266223/12 20.06.2012

Bladt S, Wagner H. "Umckaloabo"-Droge der afrikanischen Volksmedizin. *Dtsch Apoth Ztg* 1977, 117: 1655-1660

Bladt S, Wagner H. Cumarindrogen: Qualitätsprüfung der Umcka-Droge und ihrer Zubereitungen. *Dtsch Apoth Ztg* 1988, 128: 292-296

Bladt S, Wagner H. From the Zulu medicine to the European phytomedicine Umckaloabo®. *Phytomedicine* 2007, 14: 2-4

Blochin B, Haidvogl M, Heger M. Umckaloabo im Vergleich zu Acetylcystein bei Kindern mit acuter Bronchitis: prospektive, randomisierte, kontrollierte, offene Studie zur Wirksamkeit und Verträglichkeit. *Der Kassenarzt* 1999, 49: 46-50



Brendler T, van Wyk BE. A historical, scientific and commercial perspective on the medicinal use of *Pelargonium sidoides* (Geraniaceae). *J Ethnopharmacol* 2008, 119:420-433

Chuchalin AG, Berman B, Lehmacher W. Treatment of acute bronchitis in adults with *Pelargonium sidoides* preparation (EPs® 7630): a randomized, double-blind, placebo-controlled trial. *Explore* 2005, 1:437-445

Conrad A, Frank U. Extract of *Pelargonium sidoides* (EPs® 7630) displays anti-infective properties by enhanced phagocytosis and differential modulation of host-bacteria interactions. *Planta Med* 2008, 74:682-685

Conrad A, Hansmann C, Engels I, Daschner FD, Frank U. Extract of *Pelargonium sidoides* (EPs® 7630) improves phagocytes, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro. *Phytomedicine* 2007a, 14:46-51

Conrad A, Jung I, Tioua D, Lallemand C, Carrapatoso F, Engels I, et al. Extract of *Pelargonium sidoides* (EPs® 7630) inhibits the interaction of group A-streptococci and host epithelia in vitro. *Phytomedicine* 2007b, 14:52-59

Conrad A, Kolodziej H, Schulz V. Pelargonium sidoides-Extrakt (EPs® 7630): Zulassung bestätigt Wirksamkeit und Verträglichkeit. *Wien Med Wochenschr* 2007c, 157:331-336

Conrad A, Schulz V. Umckaloabo bei acuter Bronchitis. *Dtsch Apoth Ztg* 2007, 147:87-91

de Boer HJ, Hagemann U, Bate J, Meyboom HB. Allergic reactions to medicines derived from *Pelargonium* species. *Drug Safety* 2007, 30:677-680

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, OJ L 311, 28.11.2001, p. 67

Dome L, Schuster R. Umckaloabo – a phytopharmaceutical alternative for treatment of acute bronchitis in childhood? [Umckaloabo – eine phytotherapeutische Alternative bei akuter Bronchitis im Kindesalter?]. *Ärztezeitschrift für Naturheilverfahren* 1996, 37(3):216-222

Dorfmüller A, Jung I, Tioua D, Lallemand C, Engels I, Daschner FD, et al. Indirekte antibakterielle Wirkmechanismus des *Pelargonium sidoides*-Wurzelextraktes EPs® 7630: Hemmung der Interaktion von A-Streptokokken und HEp-2-Zellen. *Z Phytother* 2005, 26:S6-S7

Egan D, O'Kennedy R, Moran E, Cox D, Prosser E, Thornes RD. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. *Drug Metab Rev* 1990, 22:503-529

European Pharmacopoeia 9th ed. Pelargonium root. Council of Europe. 01/2008: 2264 corrected 6.0

Franco L, de Oliveira BH. Determination of umckalin in commercial tincture and phytopreparations containing *Pelargonium sidoides* by HPLC: Comparison of sample preparation procedure. *Talanta* 2010, 81:1368-1372

Golovatiouk A, Chuchalin AG. Efficacy of an extract from *Pelargonium sidoides* (EPs® 7630) compared to placebo in patients with acute bronchitis. [Wirksamkeit eines Extraktes aus *Pelargonium sidoides* (EPs® 7630) im Vergleich zu Placebo bei Patienten mit akuter Bronchitis]. In V, Rietbrock N, Roots I, Loew D, editors. *Phytopharmaka VII*. Darmstadt 2002, 3–12

Gödecke T, Kaloga M, Kolodziej H. A phenol glucoside, uncommon coumarins and flavonoids from *Pelargonium sidoides* DC. *Z Naturforsch B* 2005, 60:677-682

Gruenwald J, Graubaum HJ, Busch R. Efficacy and tolerability of a fixed combination of thyme and primrose root in patients with acute bronchitis. A double-blind, randomized, placebo-controlled clinical trial. *Arzneimittelforschung* 2005, 55(11):669-676

Haidvogl M, Schuster R, Heger M. Acute bronchitis in childhood. Multi-centre study of the efficacy and tolerance of the phytotherapeutic preparation Umckaloabo. [Akute Bronchitis im Kindesalter - Multizenter-Studie zur Wirksamkeit und Verträglichkeit des Phytotherapeutikums Umckaloabo]. *Zeitschrift für Phytotherapie* 1996, 17 (5): 300–313

Haidvogl M, Heger M. Treatment effect and safety of EPs® 7630-solution in acute bronchitis in childhood: Report of a multicentre observational study. *Phytomedicine* 2007, 14:60-64

Heger M, Bereznov VV. Nicht-streptokokkenbedingte Tonsillopharyngitis bei Kindern: Wirksamkeit eines Extraktes aus *Pelargonium sidoides* (EPs® 7630) im Vergleich zu Placebo. In: Schulz V, Rietbrock N, Roots I, Loew D, editors. *Phytopharmaka VII-Forschung und klinische Anwendung*. Steinkopff-Verlag, Darmstadt 2002, 13-25

Helmstädtner A. Umckaloabo – Late vindication of a secret remedy. *Pharm Historian* 1996, 26:2-4

Kamin W, Maydannik VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis. A randomized, double-blind, placebo-controlled clinical dose-finding study. *Acta Paediatr* 2010a, 99:537-543

Kamin W, Maydannik VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis: a randomized, double-blind, placebo-controlled multi-center trial with a herbal drug preparation from *Pelargonium sidoides* roots. *J Clin Pharm Ther* 2010b, 48:184-191

Kamin W, Ilyenko L, Malek F, Kieser M. Treatment of acute bronchitis with EPs 7630: Randomised, controlled trial in children and adolescents. *Pediatr Int* 2012, 54(2):219-26

Kardos P, Lehrl S, Kamin W, Matthys H. Assessment of the Effect of Pharmacotherapy in Common Cold/Acute Bronchitis – the Bronchitis Severity Scale (BSS). [Beurteilung der Wirksamkeit von Pharmakotherapie bei Erkältungen/akuter Bronchitis: Bronchitis Severity Scale (BSS)]. *Pneumologie* 2014, 68(8):542-546

Kayser O, Kolodziej H. Highly oxygenated coumarins form *Pelargonium sidoides*. *Phytochemistry* 1995, 39:1181-1185

Kayser O, Kolodziej H. Antibacterial activity of extract and constituents of *Pelargonium sidoides* and *Pelargonium reniforme*. *Planta Med* 1997, 63:508-510

Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of *Pelargonium sidoides*. *Phytother Res* 2001, 15:122-126

Kim CE, Griffiths WJ, Taylor PW. Components derived from *Pelargonium* stimulate macrophage killing of *Mycobacterium* species. *J Appl Microbiol* 2009, 106:1184-1193

Koch E. Untersuchungen zu möglichen hepatotoxischen Effekten von Umckaloabo®. *Z Phytother* 2006, 27:25

Koch E, Biber A. Treatment of rats with the *Pelargonium sidoides* extract EPs® 7630 has no effect on blood coagulation parameters or on the pharmacokinetics of warfarin. *Phytomedicine* 2007, 14:40-45

Koch E, Lanzendorfer-Gossen H, Wohn C. Stimulation of interferon (IFN)-beta synthesis and natural killer (NK) cell activity by an aqueous-ethanolic extract from roots of *Pelargonium sidoides* (Umckaloabo). *Naunyn Schmiedebergs Arch Pharmacol* 2002, 365(1):R75

Koch E, Wohn C. *Pelargonium sidoides* root extract EPs® 7630 stimulates release of antimicrobial peptides from neutrophil granulocytes in human whole blood. *Planta Med* 2007, 73:846

Kolodziej H. Traditionally used *Pelargonium* species: chemistry and biological activity of umckaloabo extracts and their constituents. *Curr Topic Phytochem* 2000, 3:77-93

Kolodziej H. *Pelargonium reniforme* and *Pelargonium sidoides* – their botany, chemistry and medicinal use. In: Lis-Balchin M, editor. Geranium and Pelargonium. Taylor & Francis, London 2002, 262-290

Kolodziej H. Fascinating metabolic pools of *Pelargonium sidoides* and *Pelargonium reniforme*, traditional and phytomedicinal sources of the herbal medicine Umckaloabo®. *Phytomedicine* 2007, 14:9-17

Kolodziej H. Aqueous ethanolic extract of the roots of *Pelargonium sidoides* – New scientific evidence for an old anti-infective phytopharmaceutical. *Planta Med* 2008, 74:661-666

Kolodziej H, Burmeister A, Trun V, Radtke OA, Kiderlen AF, Ito H, Hatano T, Yoshida T, Foo LY. Tannins and related compounds induce nitric oxide synthase and cytokines gene expressions in Leishmania mayor-infected macrophage-like RAW 264.7 cells. *Bioorg Med Chem* 2005, 13:6470-6476

Kolodziej H, Kayser O, Radtke OA, Kiderlen AF, Koch E. Pharmacological profile of extracts of *Pelargonium sidoides* and their constituents. *Phytomedicine* 2003, 10:18-24

Kolodziej H, Kayser O, Tan N. Novel coumarin sulphates from *Pelargonium sidoides*: isolation, structure and synthetic approach. In: Rauter A, Araujo E, Sales F, Justino J, Santos SP, editors. Natural Products in the New Millennium: Prospects and Industrial Application. *Proceedings of the Phytochemical Society of Europe* 2002, 59-64

Kolodziej H, Kiderlen AF. In vitro evaluation of antibacterial and immunomodulatory activities of *Pelargonium reniforme*, *Pelargonium sidoides* and the related herbal drug preparation EPs® 7630. *Phytomedicine* 2007, 14:18-26.

Lake BG. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. *Food Chem Toxicol* 1999, 37:423-453

Latte KP, Kaloga M, Kolodziej H. Reniformin, a unique diterpene ester from the roots of *Pelargonium reniforme*. *Nat Prod Commun* 2007, 2:883-886

Latte KP, Kayser O, Tan N, Kaloga M, Kolodziej H. Unusual coumarin patterns of *Pelargonium* species forming the origin of the traditional herbal medicine Umckaloabo. *Z Naturforsch B* 2000, 55:528-533

Lehrl S. Report on the Validity of the Bronchitis Severity Scale (BSS) – a scale for acute bronchitis. 14 November 2012 (unpublished report provided by Dr. Willmar Schwabe GmbH & Co. KG).

Lehrl S, Matthys H, Kamin W, Kardos P. The BSS - A Valid Clinical Instrument to Measure the Severity of Acute Bronchitis. *J Lung Pulm Respir Res* 2014, 1(3):00016

Lewu FB, Grierson DS, Afolayan AJ. Extracts from *Pelargonium sidoides* inhibit the growth of bacteria and fungi. *Pharm Biol* 2006a, 44:279-282

Lewu FB, Grierson DS, Afolayan AJ. The leaves of *Pelargonium sidoides* may substitute for its roots in the treatment of bacterial infections. *Biol Conserv* 2006b, 128:582-584

Lizogub VG, Riley DS, Heger M. Efficacy of *Pelargonium sidoides* preparation in patients with the common cold: a randomized, double-blind, placebo-controlled clinical trial. *Explore* 2007, 3:573-584

Loew D, Koch E. Coumarine- Differenzierte Risikobetrachtung mit bōdem Beispiel eines pflanzlichen Arzneimittels. *Z Phytother* 2008, 29:28-36

Mativandlela S, Lall N, Meyer J. Antibacterial, antifungal and antitubercular activity of *Pelargonium reniforme* and *Pelargonium sidoides* root extracts. *S Afr J Bot* 2006, 72:232-237

Matthys H, Eisebitt R, Seith B, Heger M. Efficacy and safety of an extract of *Pelargonium sidoides* (EPs® 7630) in adults with acute bronchitis. *Phytomedicine* 2003, 10:7-17

Matthys H, Funk P. EPs® 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomized, double-blind, placebo-controlled, multicentre trial. *Planta Med* 2008, 74:686-692

Matthys H, Heger M. Treatment of acute bronchitis in adults with a liquid herbal drug preparation from *Pelargonium sidoides* (EPs® 7630): a randomized, double-blind, placebo-controlled, multicentre study. *Curr Med Res Opin* 2007a, 23:323-331

Matthys H, Heger M. EPs® 7630 solution – an effective therapeutic option in acute and exacerbating bronchitis. *Phytomedicine* 2007b, 14:65-68

Matthys H, Kamin W, Funk P, Heger M. *Pelargonium sidoides* preparation (EPs® 7630) in the treatment of acute bronchitis in adults and children. *Phytomedicine* 2007, 14:69-73

Matthys H, Kamin W. EPs 7630, a Herbal Drug Preparation for Treating Acute Bronchitis in Children and Adults. InTechOpen 2011. Available at: <http://www.intechopen.com/books/approaches-to-bronchitis/eps-7630-a-herbal-drug-preparation-for-treating-acute-bronchitis-in-children-and-adults>.

Accessed 08/03/2016

Matthys H, Köhler S. Safety and tolerability of EPs® 7630 (Umckaloabo®). *Planta Medica* 2010, 76: 1185

Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. *CMRO* 2013, 29(10):1383-1390

Matthys H, Lizogub VG, Funk P, Malek FA. *Pelargonium sidoides* bei akuter Bronchitis – Gesundheitsbezogene Lebensqualität und Therapiebeurteilung aus Patientensicht unter Behandlung mit EPs 7630. *Wien Med Wochenschr* 2010a; 160(21-22):564-570

Matthys H, Lizogub VG, Funk P, Malek FA. Pelargonium sidoides in acute bronchitis – Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment.
[Gesundheitsbezogene Lebensqualität und Therapiebeurteilung aus Patientensicht unter Behandlung mit EPs 7630] - Translation from *Wien Med Wochenschr* 2010c, 160(21-22):1-7

Matthys H, Lizogub VG, Malek FA, Kieser M. Efficacy and tolerability of EPs® 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from *Pelargonium sidoides*. *CurrMed Res Opin* 2010b, 26(6):1413-1422

Neugebauer P, Mickenhagen A, Siefer O, Walger M. A new approach to pharmacological effects on ciliary beat frequency in cell cultures – exemplary measurements under *Pelargonium sidoides* extract (EPs® 7630). *Phytomedicine* 2005, 12:46-51

Niho N, Shibusawa M, Tamura T, Toyoda K, Uneyama C, Takahashi N, et al. Subchronic toxicity study of gallic acid by oral administration in F344 rats. *Food Chem Toxicol* 2001, 39:1063-1070

Nöldner M, Schötz K. Inhibition of lipopolysaccharide-induced sickness behaviour by a dry extract from the roots of *Pelargonium sidoides* (EPs® 7630) in mice. *Phytomedicine* 2007, 14:27-31

Patience S, Mativandlela N, Meyer JJM, Hussein AA, Lall N. Antitubercular activity of compounds isolated from *Pelargonium sidoides*. *Pharm Biol* 2007, 45:645-650

Patrick G, Hickner J. This obscure herb works for the common cold. *J Fam Practice* 2008, 57:157-161

Rajalakshmi K, Devaraj H, Devaraj SN. Assessment of the no-observed-adverse-effect level (NOAEL) of gallic acid in mice. *Food Chem Toxicol* 2001, 39:919-922

Schapowal A, Heger M. EPs® 7630 Lösung (Umckaloabo®) bei Sinusitis. *Z Phytother* 2007, 28:58-65

Schnitzler P, Schneider S, Stintzing FC, Carle R, Reichling J. Efficacy of an aqueous *Pelargonium sidoides* extract against herpes virus. *Phytomedicine* 2008, 15:1108-1116

Schötz K, Erdelmeier C, Germer S, Hauer H. A detailed view on the constituents of EPs® 7630. *Planta Med* 2008, 74:667-674

Schötz K, Nödler M. Mass spectroscopic characterization of oligomeric proanthocyanidins derived from an extract of *Pelargonium sidoides* roots (EPs® 7630) and pharmacological screening in CNS models. *Phytomedicine* 2007, 14:32-39

Schulz V. Auszug aus *Pelargonium sidoides*- Wurzel wirksam bei akuter Bronchitis Ergebnisse einer Doppelblindstudie mit 124 Patienten. *Z Phytother* 2006, 27:237-238

Schulz V. Liquid herbal drug preparation from the root of *Pelargonium sidoides* is effective against acute bronchitis: Results of double-blind study with 124 patients. *Phytomedicine* 2007, 14: SVI74-7521

Schulz V. Dosisfindindungstudie zur Wirksamkeit von *Pelargonium sidoides* extrakt (EPs® 7630 in neuer Tablettenform) bei 405 Erwachsenen mit acuter Bronchitis. *Z Phytother* 2008a, 29:37-38

Schulz V. Akute Bronchitis – Kongressbericht über zwei neue Doppelblindstudien zur Wirksamkeit und Vertraglichkeit von *Pelargonium sidoides* Extrakt (EPs® 7630) bei 420 Kindern and Jugendlichen. *Z Phytother* 2008b, 29:38-39

Seidel V, Taylor P. In vitro activity of extract and constituents of *Pelargonium* against rapidly growing mycobacteria. *Int J Antimicrob Agents* 2004, 23:613-619

Taylor P, Maalim S, Coleman S. The strange story of umckaloabo. *Pharm J* 2005, 275:790-792

Teschke R, Frenzel C, Schulze J, Eikhoff A. Spontaneous reports of primarily suspected hepatotoxicity by *Pelargonium sidoides*: Was causality adequately ascertained? *Regul Toxicol Pharmacol* 2012a, 63:1-9

Teschke R, Frenzel C, Wolff A, Herzog J, Glass X, Schulze J, et al. Initially purported hepatotoxicity by *Pelargonium sidoides*: the dilemma of pharmacovigilance and proposals for improvement. *Ann Hepatol* 2012b, 11:500-512

Thäle C, Kiderlen A, Kolodziej H. Anti-infective mode of action of EPs® 7630 at the molecular level. *Planta Med* 2008, 74:675-681

Timmer A, Günther J, Rücker G, Motschall E, Antes G, Kern WV. *Pelargonium sidoides* extract for acute respiratory tract infections. *Cochrane Database Syst Rev* 2009, 3:CD006323

Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV. *Pelargonium sidoides* extract for treating acute respiratory tract infections (Review) The Cochrane Library 2013, Issue 10

Trun W, Kiderlen AF, Kolodziej H. Nitric oxide synthase and cytokines gene expression analyses in Leishmania-infected RAW 264.7 cells treated with an extract of *Pelargonium sidoides* (EPs® 7630). *Phytomedicine* 2006, 13:570-575

van Wyk BE. A broad review of commercially important southern African medicinal plants. *J Ethnopharmacol* 2008, 119:342-355

Wittschier N, Faller G, Hensel A. An extract of *Pelargonium sidoides* (EPs® 7630) inhibits *in situ* adhesion of *Helicobacter pylori* to human stomach. *Phytomedicine* 2007; 14:285-288

White AG, Davies-Coleman MT, Ripley BS. Measuring and optimising concentration in wild-harvest and cultivated *Pelargonium sidoides* (Geraniaceae). *S Afr J Bot* 2008; 74:260-267

References assessed but not included in the Assessment report

Agbabiaka TB, Guo R, Ernst E. *Pelargonium sidoides* for acute bronchitis: A systemic review and meta-analysis. *Phytomedicine* 2008; 15:378-385

Arold G, Wollny A. Final report. A placebo-controlled, double-blind, parallel-group interaction study of an Umckaloabo preparation and penicillin V in 28 healthy subjects. Study No.: 88801.01.029. Berlin 2003 [unpublished study report, provided by Dr. Willmar Schwabe GmbH & Co. KG]

Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd Ed. Hillsdale: Lawrence Erlbaum Associates, 1988

Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. *BMJ* 1995; 310:452–454

Heger M. Wirksamkeit und Verträglichkeit eines Extraktes aus *Pelargonium sidoides* (EPs® 7630) bei akuter Bronchitis. Ergebnisse einer multizentrischen doppelblinden, placebokontrollierten Studie. [Efficacy and tolerability of an extract from *Pelargonium sidoides* (EPs® 7630) in acute bronchitis. Results from a multicenter double-blind placebo-controlled study]. Abstract from Phytopharma und Phytotherapie – Forschung und Praxis, Berlin, October 10–12, 2002

Malek FA. Efficacy and tolerability of *Pelargonium sidoides* extract EPs 7630 in patients (1 to 18 years old) with acute bronchitis: A randomized, double-blind, placebo-controlled clinical trial [Study No. 70100.01.001]. Karlsruhe 2007a [unpublished clinical trial, provided by Dr. Willmar Schwabe GmbH & Co.KG]

Malek FA, Köhler S, Kieser M, Buschulte I. Efficacy and tolerability of EPs 7630-filmcoated tablets in patients (6 to 18 years old) with acute bronchitis: A randomised, double-blind, placebo-controlled clinical dose-finding study [Study No. 701003.01.002]. Karlsruhe 2007b [unpublished study report, provided by Dr. Willmar Schwabe GmbH & Co.KG]

Malek FA, Köhler S, Kieser M, Buschulte I. Efficacy and tolerability of EPs 7630-filmcoated tablets in patients (>18 years old) with acute bronchitis: A randomized, double-blind, placebo-controlled clinical dose-finding study [Study-No. 701003.01.003]. Karlsruhe 2007c [unpublished study report, provided by Dr. Willmar Schwabe GmbH & Co.KG]

Malek FA, Köhler S, Kieser M, Buschulte I. Efficacy and tolerability of EPs 7630, a liquid herbal drug preparation from *Pelargonium sidoides* in patients (1-18 years old) suffering from acute bronchitis: A randomized, double-blind, placebo-controlled clinical trial [Study-No. 701003.01.004]. Karlsruhe 2007d [unpublished study report, provided by Dr. Willmar Schwabe GmbH & Co.KG]

Mwachari C, Nduba V, Nguti R, Park DR, Sanguli L, Cohen CR. Validation of a new clinical scoring system for acute bronchitis. *The International Journal of Tuberculosis and Lung Disease* 2007; 11: 1253-1259.

Neidig C. Clinical study report. Efficacy of EPs® 7630 in the treatment of acute angina catarrhalis. [Wirksamkeit von EPs® 7630 bei akuter Angina catarrhalis]. Cologne 2002a [unpublished study report, provided by Dr. Willmar Schwabe GmbH & Co.KG]

Neidig C. Clinical study report. Efficacy of EPs® 7630 in the treatment of acute angina catarrhalis. [Wirksamkeit von EPs® 7630 bei akuter Angina catarrhalis]. Cologne 2002b [unpublished study report, provided by Dr. Willmar Schwabe GmbH & Co.KG]

Vornbäumen J. and Eisebitt R. Biometrial report. Efficiency of Umckaloabo compared to acetylcysteine in acute bronchitis. Cologne - 1998, 1-20 [unpublished report, provided by Dr. Willmar Schwabe GmbH & Co.KG]

Zind U, Reineke T, Buschulte I. Investigation on the safety of EPs® 7630 after continuous treatment over 6 weeks in 2 different dosages: A placebo-controlled trial in healthy volunteers. Ettlingen 2011 [unpublished study report, provided by Dr. Willmar Schwabe GmbH & Co.KG]